All In Biotech

Drug Trial Radar · NCT06176040

A Study of TAVO101 in Atopic Dermatitis Patients

A Pilot Phase 2A Study to Examine the Preliminary Efficacy, Safety and PK of TAVO101 in Patients with Moderate to Severe Atopic Dermatitis (AD)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 15, 2024

Primary completion

Mar 15, 2025

Study completion Jun 15, 2025

Sponsor

Lead sponsor
Tavotek BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.

Conditions

  • Atopic Dermatitis

Interventions

  • TAVO101Drug

    TAVO101 IV Infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who achieve a 50% Reduction From Baseline in Eczema Area and Severity (EASI 50) at Week 16Time frame: Baseline to Week 16

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Optimal Clinical Trials

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.